Insider plans Rule 144 sale of 1,976 Bio-Techne (TECH) shares

Rhea-AI Filing Summary

A holder of Bio-Techne (TECH) common stock filed a Rule 144 notice to sell 1976 shares through Morgan Stanley Smith Barney on or around 02/17/2026 on NASDAQ, with an aggregate market value of $116791.48.

The shares to be sold are part of the company’s common stock, which had 156453292 shares outstanding listed as a baseline figure. The seller acquired these 1976 shares on 02/14/2025 by exercising previously granted stock options and paid the purchase price in cash.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1976	116791.48	156453292	02/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/14/2025	Previously Exercised Options	Issuer			1976	02/14/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Bio-Techne (TECH) disclose in this Form 144 filing?

Bio-Techne (TECH) discloses a planned Rule 144 sale of 1976 common shares. A shareholder intends to sell these shares on NASDAQ through Morgan Stanley Smith Barney, with an aggregate market value of $116791.48, after acquiring them via option exercise.

How many Bio-Techne (TECH) shares are planned to be sold and at what value?

The filing covers 1976 Bio-Techne common shares with a market value of $116791.48. These shares are planned for sale on NASDAQ through Morgan Stanley Smith Barney Executive Financial Services, under Rule 144 resale provisions for restricted or controlled stock.

When and how were the Bio-Techne (TECH) shares being sold under Rule 144 acquired?

The 1976 shares were acquired on 02/14/2025 by exercising options. The holder obtained the shares directly from the issuer through previously exercised stock options and paid the purchase price in cash on the same date, before planning this Rule 144 resale.

Which broker is handling the planned Rule 144 sale for Bio-Techne (TECH) shares?

The planned sale will be executed through Morgan Stanley Smith Barney LLC. The filing lists its Executive Financial Services group at 1 New York Plaza, New York, as the broker handling the 1976-share NASDAQ transaction for the shareholder under Rule 144.

How does the planned Rule 144 sale compare to Bio-Techne (TECH) shares outstanding?

The notice lists 156453292 Bio-Techne common shares outstanding. The planned sale of 1976 shares is a very small portion of this baseline figure, indicating a limited relative size compared with the total outstanding common stock reported in the form.

What representation does the selling holder make in this Bio-Techne (TECH) Form 144?

The selling holder represents they know no undisclosed material adverse information. By signing, they state they are unaware of negative, non-public information about Bio-Techne’s current or prospective operations in connection with this planned Rule 144 sale of common shares.